# Synapse Protein Signatures in Cerebrospinal Fluid and Plasma Predict Cognitive Maintenance vs Decline in Alzheimer's Disease

## TL;DR

A new biomarker based on synapse proteins in cerebrospinal fluid and blood can predict cognitive decline in Alzheimer's disease more accurately than existing markers.

## Contribution

Identifies a novel synapse protein ratio (YWHAG:NPTX2) in CSF and plasma as a strong predictor of cognitive outcomes in Alzheimer's disease.

## Key findings

- The CSF YWHAG:NPTX2 ratio explains significant variance in cognitive impairment beyond existing AD biomarkers.
- Plasma proteomic signatures partly mirror the CSF YWHAG:NPTX2 findings, offering a non-invasive alternative.
- APOE4 carriers and autosomal dominant-AD mutation carriers show faster increases in YWHAG:NPTX2 with aging.

## Abstract

Rates of cognitive decline in Alzheimer's disease (AD) are extremely heterogeneous, with symptom onset occurring between ages 40‐100 years and conversion from mild cognitive impairment (MCI) to AD dementia occurring in 2‐20 years. Biomarkers for amyloid‐beta (Aβ) and tau proteins, the hallmark AD pathologies, have improved diagnosis and drug development but explain only 20‐40% of the variance in AD‐related cognitive impairment (CI).

To discover additional biomarkers of CI in AD, we perform cerebrospinal fluid (CSF) proteomics on 3,397 individuals from six major prospective AD case‐control cohorts. Synapse proteins emerge as the strongest correlates of CI, independent of Aβ and tau.

Using machine learning, we derive the CSF YWHAG:NPTX2 synapse protein ratio, which explains 27% of the variance in CI beyond CSF PTau181:Aβ42, 10% beyond tau PET, and 28% beyond CSF NfL, GAP43, and Ng in Aβ‐ and phosphorylated tau‐ positive (A+T1+) individuals. We find YWHAG:NPTX2 also increases with normal aging and at a faster rate in APOE4 carriers and autosomal dominant‐AD mutation carriers. For prognosis, we define YWHAG:NPTX2 thresholds to stratify A+T1+ individuals into five groups that track with future cognitive resilience versus decline. Most notably, among A+T1+ MCI individuals, those in the predicted cognitively normal group have a 73% reduced risk of cognitive decline, while those in the predicted dementia group have a 2.3 times increased risk, after adjusting for CSF PTau181:Aβ42, CSF NfL, CSF Ng, CSF GAP43, age, APOE4, and sex. Lastly, we develop a plasma proteomic signature of CI, which we evaluate in 13,401 samples, that partly recapitulates CSF YWHAG:NPTX2.

Overall, our findings underscore CSF YWHAG:NPTX2 and the corresponding plasma signature as robust prognostic biomarkers for AD onset and progression beyond gold‐standard biomarkers of Aβ, tau, and neurodegeneration and implicate synapse dysfunction as a core driver of AD dementia.